Terms: = Prostate cancer AND RHOA, ENSG00000067560, 387, ARHA, RhoA, RHOH12, RHO12, ARH12, Rho12 AND Treatment
100 results:
1. Development of risk-score model in patients with negative surgical margin after robot-assisted radical prostatectomy.
Yamada Y; Fujii Y; Kakutani S; Kimura N; Sugimoto K; Hakozaki Y; Sugihara T; Takeshima Y; Kawai T; Nakamura M; Kamei J; Taguchi S; Akiyama Y; Sato Y; Yamada D; Urabe F; Miyazaki H; Enomoto Y; Fukuhara H; Nakagawa T; Fujimura T; Kume H
Sci Rep; 2024 Mar; 14(1):7607. PubMed ID: 38556562
[TBL] [Abstract] [Full Text] [Related]
2. Assessment of the Surgical Oncology Case Volume Within the Public Sector in Tanzania.
Brand NR; Akoko L; Kotecha V; Mwakyembe T; Mwashambwa M; Hamid R; Hando D; Komba C; Mwanga A; Mbele P; Itule P; Jackson J; Misidai M; Gaskill C; Ozgediz D
JCO Glob Oncol; 2024 Mar; 10():e2300316. PubMed ID: 38452305
[TBL] [Abstract] [Full Text] [Related]
3. The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤4 cm.
Tappero S; Barletta F; Piccinelli ML; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Parodi S; Dell'Oglio P; Palumbo C; Briganti A; De Cobelli O; Chun FKH; Graefen M; Longo N; Ahyai S; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
Eur Urol Focus; 2023 Sep; 9(5):742-750. PubMed ID: 36906483
[TBL] [Abstract] [Full Text] [Related]
4. Gold Nanosystems Covered with Doxorubicin/DNA Complexes: A Therapeutic Target for prostate and Liver cancer.
Giráldez-Pérez RM; Grueso E; Montero-Hidalgo AJ; Luque RM; Carnerero JM; Kuliszewska E; Prado-Gotor R
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555216
[TBL] [Abstract] [Full Text] [Related]
5. Ulinastatin ameliorates the malignant progression of prostate cancer cells by blocking the rhoa/ROCK/NLRP3 pathway.
Liu Z; Zhu X; Xu C; Min F; Yu G; Chen C
Drug Dev Res; 2023 Feb; 84(1):36-44. PubMed ID: 36461611
[TBL] [Abstract] [Full Text] [Related]
6. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant prostate cancer: An Indirect Comparison.
Shore N; Jiang S; Garcia-Horton V; Terasawa E; Steffen D; Chin A; Ayyagari R; Partridge J; Waldeck AR
Adv Ther; 2022 Nov; 39(11):5025-5042. PubMed ID: 36028656
[TBL] [Abstract] [Full Text] [Related]
7. Knockdown of rhoa Expression Reverts Enzalutamide Resistance via the p38 MAPK Pathway in Castration-resistant prostate cancer.
Chen X; Yin L; Xu H; Rong J; Feng M; Jiang D; Bai Y
Recent Pat Anticancer Drug Discov; 2023; 18(1):92-99. PubMed ID: 35339190
[TBL] [Abstract] [Full Text] [Related]
8. Patterns of Metastatic Disease in Patients with cancer Derived from Natural Language Processing of Structured CT Radiology Reports over a 10-year Period.
Do RKG; Lupton K; Causa Andrieu PI; Luthra A; Taya M; Batch K; Nguyen H; Rahurkar P; Gazit L; Nicholas K; Fong CJ; Gangai N; Schultz N; Zulkernine F; Sevilimedu V; Juluru K; Simpson A; Hricak H
Radiology; 2021 Oct; 301(1):115-122. PubMed ID: 34342503
[TBL] [Abstract] [Full Text] [Related]
9. Human Tissue Kallikrein 1 Is Downregulated in Elderly Human prostates and Possesses Potential In Vitro Antioxidative and Antifibrotic Effects in Rodent prostates.
Zhang M; Luo C; Lin D; Cui K; Chen Z; Liu J
Oxid Med Cell Longev; 2021; 2021():8877540. PubMed ID: 34007408
[TBL] [Abstract] [Full Text] [Related]
10. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
11. Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation.
Rentz AM; Mansukhani SG; Liu J; Lloyd AJ; Heidenreich S; Matza LS; Dawson NA; Shore N; Freedland SJ
Urol Oncol; 2021 Jun; 39(6):367.e7-367.e17. PubMed ID: 33736976
[TBL] [Abstract] [Full Text] [Related]
12. Men's sexual help-seeking and care needs after radical prostatectomy or other non-hormonal, active prostate cancer treatments.
Hyde MK; Opozda M; Laurie K; Vincent AD; Oliffe JL; Nelson CJ; Dunn J; Chung E; Gillman M; Manecksha RP; Wittert G; Chambers SK
Support Care Cancer; 2021 May; 29(5):2699-2711. PubMed ID: 32978635
[TBL] [Abstract] [Full Text] [Related]
13. rhoa/ROCK pathway inhibitor ameliorates erectile dysfunction induced by radiation therapy in rats.
Mahmood J; Pandita R; Zhang A; Kamlapurkar S; Saeed A; Chen M; Staats PN; Shukla HD; Anvari A; Sawant A; Vujaskovic Z
Radiother Oncol; 2020 Sep; 150():174-180. PubMed ID: 32565390
[TBL] [Abstract] [Full Text] [Related]
14. Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
Simmons AD; Nguyen M; Pintus E
BMC Cancer; 2020 Mar; 20(1):215. PubMed ID: 32171277
[TBL] [Abstract] [Full Text] [Related]
15. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
[TBL] [Abstract] [Full Text] [Related]
16. Utility of Multiparametric Magnetic Resonance Imaging With PI-RADS, Version 2, in Patients With prostate cancer Eligible for Active Surveillance: Which Radiologic Characteristics Can Predict Unfavorable Disease?
Kim H; Pak S; Park KJ; Kim MH; Kim JK; Kim M; You D; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
Clin Genitourin Cancer; 2020 Feb; 18(1):50-55. PubMed ID: 31640913
[TBL] [Abstract] [Full Text] [Related]
17. Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.
Venkadakrishnan VB; DePriest AD; Kumari S; Senapati D; Ben-Salem S; Su Y; Mudduluru G; Hu Q; Cortes E; Pop E; Mohler JL; Azabdaftari G; Attwood K; Shah RB; Jamieson C; Dehm SM; Magi-Galluzzi C; Klein E; Sharifi N; Liu S; Heemers HV
Oncogene; 2019 Jun; 38(23):4496-4511. PubMed ID: 30742064
[TBL] [Abstract] [Full Text] [Related]
18. Zoledronic Acid Inhibits the rhoa-mediated Amoeboid Motility of prostate cancer Cells.
Pietrovito L; Comito G; Parri M; Giannoni E; Chiarugi P; Taddei ML
Curr Cancer Drug Targets; 2019; 19(10):807-816. PubMed ID: 30648509
[TBL] [Abstract] [Full Text] [Related]
19. Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based study.
Pompe RS; Smith A; Bandini M; Marchioni M; Martel T; Preisser F; Leyh-Bannurah SR; Schiffmann J; Saad F; Huland H; Graefen M; Shariat SF; Tilki D; Karakiewicz PI
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):71-77. PubMed ID: 29339806
[TBL] [Abstract] [Full Text] [Related]
20. Agonist-induced CXCR4 and CB2 Heterodimerization Inhibits Gα13/rhoa-mediated Migration.
Scarlett KA; White EZ; Coke CJ; Carter JR; Bryant LK; Hinton CV
Mol Cancer Res; 2018 Apr; 16(4):728-739. PubMed ID: 29330286
[TBL] [Abstract] [Full Text] [Related]
[Next]
